Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

OBJECTIVE: To evaluate the comparative efficacy and safety of the 4 currently available hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, fluvastatin, lovastatin, pravastatin, and simvastatin, in the treatment of primary hypercholesterolemia. DATA SOURCES: English-language clinical studies, abstracts, and review articles identified from MEDLINE searches and bibliographies of identified articles. Unpublished data were obtained from the Food and Drug Administration in accordance with the Freedom of Information Act. STUDY SELECTION: Placebo-controlled and comparative studies of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. DATA EXTRACTION: Pertinent studies were selected and the data were synthesized into a review format. DATA SYNTHESIS: The chemistry, pharmacology, and pharmacokinetics of the 4 HMG-CoA reductase inhibitors are reviewed. Clinical trials evaluating the hypocholesterolemic efficacy of the HMG-CoA reductase inhibitors are examined, and results on the comparative efficacy and safety of these agents are summarized. On a milligram-per-milligram basis, simvastatin is twice as potent as lovastatin and pravastatin. The hypocholesterolemic effects of fluvastatin appear to be approximately 30% less than that of lovastatin. In posttransplant patients receiving cyclosporine, safety has been documented for low doses of lovastatin and simvastatin, but when a higher dosage of an HMG-CoA reductase inhibitor is warranted, pravastatin should be considered the drug of choice because of a lower incidence of myopathy. Relevant data on the incidence of adverse effects are presented. Pertinent outcomes data from clinical trials evaluating the effect of HMG-CoA reductase inhibitors on atherosclerosis regression and coronary mortality, as well as published economic analyses of cholesterol-lowering agents, are summarized. Recommendations on the selection of an HMG-CoA reductase inhibitor in various clinical situations are provided. CONCLUSIONS: The literature supports the comparable safety and tolerability of all 4 currently available HMG-CoA reductase inhibitors. Therefore, the choice of an HMG-CoA reductase inhibitor should depend on the extent of cholesterol lowering needed to meet the recommended treatment goal established by the National Cholesterol Education Program. Direct comparative studies are needed to confirm the relative, long-term cost-effectiveness of the various HMG-CoA reductase inhibitors in the treatment of primary hypercholesterolemia.

This article has been cited by other articles:

				F. Gao, L. Linhartova, A. McD. Johnston, and D. R. Thickett Statins and sepsis Br. J. Anaesth., March 1, 2008; 100(3): 288 - 298. [Abstract] [Full Text] [PDF]

				B. E. K. Klein, R. Klein, K. E. Lee, and L. M. Grady Statin Use and Incident Nuclear Cataract JAMA, June 21, 2006; 295(23): 2752 - 2758. [Abstract] [Full Text] [PDF]

				Z. Zhou, E. Rahme, M. Abrahamowicz, J. V. Tu, M. J. Eisenberg, K. Humphries, P. C. Austin, and L. Pilote Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect Can. Med. Assoc. J., April 26, 2005; 172(9): 1187 - 1194. [Abstract] [Full Text] [PDF]

				J. D. Piorkowski Jr Bayer's Response to "Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis" JAMA, December 1, 2004; 292(21): 2655 - 2657. [Full Text] [PDF]

				B. E Sipe, R. J Jones, and G. H Bokhart Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction Ann. Pharmacother., June 1, 2003; 37(6): 808 - 811. [Abstract] [Full Text] [PDF]

				References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]

				R. C. Pasternak, S. C. Smith Jr, C. N. Bairey-Merz, S. M. Grundy, J. I. Cleeman, and C. Lenfant ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Stroke, September 1, 2002; 33(9): 2337 - 2341. [Full Text] [PDF]

				R. C. Pasternak, S. C. Smith Jr, C. N. Bairey-Merz, S. M. Grundy, J. I. Cleeman, C. Lenfant, and Writing Committee Members: ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Circulation, August 20, 2002; 106(8): 1024 - 1028. [Full Text] [PDF]

				R. C. Pasternak, S. C. Smith Jr, C. N. Bairey-Merz, S. M. Grundy, J. I. Cleeman, and C. Lenfant ACC/AHA/NHLBI clinical advisory on the use and safety of statins J. Am. Coll. Cardiol., August 7, 2002; 40(3): 567 - 572. [Full Text] [PDF]

				E.-j. Wang, K. Lew, C. N. Casciano, R. P. Clement, and W. W. Johnson Interaction of Common Azole Antifungals with P Glycoprotein Antimicrob. Agents Chemother., January 1, 2002; 46(1): 160 - 165. [Abstract] [Full Text] [PDF]

				H. Hiyoshi, M. Yanagimachi, M. Ito, I. Ohtsuka, I. Yoshida, T. Saeki, and H. Tanaka Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors J. Lipid Res., July 1, 2000; 41(7): 1136 - 1144. [Abstract] [Full Text]

				R. J. Herman Drug interactions and the statins Can. Med. Assoc. J., November 1, 1999; 161(10): 1281 - 1286. [Abstract] [Full Text] [PDF]

				W. Jacobsen, G. Kirchner, K. Hallensleben, L. Mancinelli, M. Deters, I. Hackbarth, K. Baner, L. Z. Benet, K.-F. Sewing, and U. Christians Small Intestinal Metabolism of the 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitor Lovastatin and Comparison with Pravastatin J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 131 - 139. [Abstract] [Full Text]

				R. H. Knopp Drug Treatment of Lipid Disorders N. Engl. J. Med., August 12, 1999; 341(7): 498 - 511. [Full Text] [PDF]

				W. Jacobsen, G. Kirchner, K. Hallensleben, L. Mancinelli, M. Deters, I. Hackbarth, L. Z. Benet, K.-Fr. Sewing, and U. Christians Comparison of Cytochrome P-450-Dependent Metabolism and Drug Interactions of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Lovastatin and Pravastatin in the Liver Drug Metab. Dispos., February 1, 1999; 27(2): 173 - 179. [Abstract] [Full Text]

				D. M. Black, R. G. Bakker-Arkema, and J. W. Nawrocki An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor Arch Intern Med, March 23, 1998; 158(6): 577 - 584. [Abstract] [Full Text] [PDF]